4.7 Article

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy

期刊

BLOOD
卷 137, 期 16, 页码 2171-2181

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2019004108

关键词

-

资金

  1. Canadian Cancer Society [704121]
  2. Princess Margaret Cancer Foundation [886012001223]
  3. Canadian Institutes of Health Research
  4. Office of Management, Information, and Research Early Researcher Award
  5. Canadian Institutes of Health Research (CIHR) New Investigator Salary Award

向作者/读者索取更多资源

AMl remains a devastating disease for which new therapies are needed. Targeted adoptive T-cell therapies have shown promise in some leukemias but not in AML. A study utilizing CRISPR/Cas9 screens identified SAGA and CD64 as key factors influencing the sensitivity of AML cells to DNT therapy.
Acute myeloid leukemia (AML) remains a devastating disease in need of new therapies to improve patient survival. Targeted adoptive T-cell therapies have achieved impressive clinical outcomes in some B-cell leukemias and lymphomas but not in AML. Double-negative T cells (DNTs) effectively kill blast cells from the majority of AML patients and are now being tested in clinical trials. However, AML blasts obtained from similar to 30% of patients show resistance to DNT-mediated cytotoxicity; the markers or mechanisms underlying this resistance have not been elucidated. Here, we used a targeted clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) screen to identify genes that cause susceptibility of AML cells to DNT therapy. Inactivation of the Spt-Ada-Gcn5-acetyltransferase (SAGA) deubiquitinating complex components sensitized AML cells to DNT-mediated cytotoxicity. In contrast, CD64 inactivation resulted in resistance to DNT-mediated cytotoxicity. Importantly, the level of CD64 expression correlated strongly with the sensitivity of AML cells to DNT treatment. Furthermore, the ectopic expression of CD64 overcame AML resistance to DNTs in vitro and in vivo. Altogether, our data demonstrate the utility of CRISPR/Cas9 screens to uncover mechanisms underlying the sensitivity to DNT therapy and suggest CD64 as a predictive marker for response in AML patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据